neoadjuvant immunotherapy
neoadjuvant immunotherapy is a pharmaceutical drug with 7 clinical trials. Currently 3 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 1 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
1
Mid Stage
2
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
100.0%
1 of 1 finished
0.0%
0 ended early
3
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Neoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC.
Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC
Omega-3 Supplementation and Immunotherapy in Gastric Cancer: A Phase II Trial
Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer
NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCC
Clinical Trials (7)
Neoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC.
Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC
Omega-3 Supplementation and Immunotherapy in Gastric Cancer: A Phase II Trial
Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer
NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCC
Real-world Clinical Outcomes of NSCLC Patients Receiving Neoadjuvant Immunotherapy
Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative Delirium
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7